Axon Enterprise, Inc (NASDAQ:AXON) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. trimmed its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 10.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 470 shares of the biotechnology company’s stock after selling 52 shares during the period. Brown Advisory Inc.’s holdings in Axon Enterprise were worth $247,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of AXON. Fourth Dimension Wealth LLC acquired a new position in shares of Axon Enterprise during the 4th quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC grew its stake in Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 33 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in shares of Axon Enterprise during the 1st quarter valued at $32,000. Alpine Bank Wealth Management purchased a new stake in shares of Axon Enterprise during the 1st quarter valued at $40,000. Finally, Elequin Capital LP purchased a new stake in shares of Axon Enterprise during the 4th quarter valued at $46,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the company’s stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $738.84, for a total value of $960,492.00. Following the completion of the transaction, the director owned 4,829 shares in the company, valued at approximately $3,567,858.36. This represents a 21.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Jennifer H. Mak sold 75 shares of the company’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the transaction, the chief accounting officer owned 15,240 shares of the company’s stock, valued at approximately $11,762,384.40. This trade represents a 0.49% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,642 shares of company stock worth $30,500,428. 4.40% of the stock is owned by company insiders.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $742.77 on Thursday. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. Axon Enterprise, Inc has a fifty-two week low of $279.02 and a fifty-two week high of $830.21. The firm has a 50-day simple moving average of $760.96 and a 200 day simple moving average of $643.52. The company has a market cap of $57.82 billion, a PE ratio of 179.41, a P/E/G ratio of 85.86 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The company’s revenue for the quarter was up 31.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AXON. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th. UBS Group initiated coverage on shares of Axon Enterprise in a report on Wednesday. They issued a “neutral” rating and a $820.00 price objective on the stock. Bank of America boosted their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a report on Wednesday, June 4th. Finally, Barclays upped their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average price target of $725.00.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.